Christian Pilarsky
Overview
Explore the profile of Christian Pilarsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
12435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiorini E, Malinova A, Schreyer D, Pasini D, Bevere M, Alessio G, et al.
Nature
. 2025 Mar;
PMID: 40074906
Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity, thereby providing a substrate for somatic evolution. Nonetheless, the...
2.
Tang Y, Tang S, Yang W, Zhang Z, Wang T, Wu Y, et al.
Gut
. 2024 Aug;
73(12):1999-2011.
PMID: 39216984
Objective: Pancreatic ductal adenocarcinoma (PDAC) stands as one of the most lethal cancers, marked by its lethality and limited treatment options, including the utilisation of checkpoint blockade (ICB) immunotherapy. Epigenetic...
3.
Bermejo-Rodriguez C, Araos Henriquez J, Caligiuri G, Pinto Teles S, Park Y, Evans A, et al.
Cancer Res
. 2024 Jul;
84(18):2968-2984.
PMID: 39037766
Perturbation of cell polarity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) progression. Scribble (SCRIB) is a well-characterized polarity regulator that has diverse roles in the pathogenesis of human neoplasms....
4.
Mottini C, Auciello F, Manni I, Pilarsky C, Caputo D, Caracciolo G, et al.
J Exp Clin Cancer Res
. 2024 Jul;
43(1):198.
PMID: 39020414
Pancreatic cancer (PC) is a clinically challenging tumor to combat due to its advanced stage at diagnosis as well as its resistance to currently available therapies. The absence of early...
5.
Podolska M, Grutzmann R, Pilarsky C, Benard A
Front Immunol
. 2024 Jun;
15:1411047.
PMID: 38938573
Interleukin (IL)-3 has long been known for its hematopoietic properties. However, recent evidence has expanded our understanding of IL-3 function by identifying IL-3 as a critical orchestrator of inflammation in...
6.
Zhang S, Yun D, Yang H, Eckstein M, Daw Elbait G, Zhou Y, et al.
Cell Death Discov
. 2024 Mar;
10(1):124.
PMID: 38461159
Pancreatic cancer is a malignant tumor of the digestive system. It is highly aggressive, easily metastasizes, and extremely difficult to treat. This study aimed to analyze the genes that might...
7.
Zhang J, Zhang S, Dorflein I, Ren X, Pfeffer S, Britzen-Laurent N, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835536
Pancreatic cancer is among the cancers with the highest mortality rates. Most of the patients are found to have advanced cancer, losing the chance of surgical treatment, and there is...
8.
Al-Fatlawi A, Rusadze E, Shmelkin A, Malekian N, Ozen C, Pilarsky C, et al.
BMC Bioinformatics
. 2023 Jul;
24(1):304.
PMID: 37516832
Background: Integrating multi-omics data is fast becoming a powerful approach for predicting disease progression and treatment outcomes. In light of that, we introduce a modified version of the NetRank algorithm,...
9.
Daunke T, Beckinger S, Rahn S, Kruger S, Heckl S, Schafer H, et al.
Front Immunol
. 2023 Jul;
14:1157397.
PMID: 37449210
Introduction: Immune checkpoint inhibitors (ICI), e.g., targeting programmed cell death protein 1-ligand 1 (PD-L1) or its receptor PD-1, have markedly improved the therapy of many cancers but so far failed...
10.
Dinter J, Friedrich R, Yang H, Pilarsky C, Mangge H, Pottler M, et al.
Materials (Basel)
. 2023 Apr;
16(7).
PMID: 37049199
Pancreatic ductal adenocarcinoma is a hard-to-treat, deadly malignancy. Traditional treatments, such as surgery, radiation and chemotherapy, unfortunately are still not able to significantly improve long-term survival. Three-dimensional (3D) cell cultures...